Study of the effectiveness and safety of a combination of a hypertonic solution and high molecular weight hyaluronic acid (Ingasalin® 3%) in the form of inhalation in the treatment of acute bronchitis against the background of acute respiratory infections in children 3-7 years old

Introduction. Cough is the most common manifestation of respiratory infections affecting the upper and lower airways, indicating impaired mucociliary clearance. Mucolytic agents are often used to normalize the patient's condition and improve mucus clearance. To normalize the patient's condition and improve mucus clearance, mucolytic agents are often used. Considering the mucolytic action of hypertonic solutions, we conducted a comparative clinical study to evaluate the efficacy and safety of a combination of 3% hypertonic saline solution and high molecular weight hyaluronic acid 0.01% (Ingasalin® 3%) in the treatment of acute bronchitis during acute respiratory infections. Objective: To evaluate the efficacy and safety of a combination of 3% hypertonic saline solution and high molecular weight hyaluronic acid 0.01% (Ingasalin® 3%) in the treatment of acute bronchitis during acute respiratory infections in children aged 3 to 7 years. Materials and Methods: The study involved 120 patients aged 3 to 7 years with acute bronchitis during acute respiratory infections (ARI). All patients were randomly assigned to two groups using simple randomization: Group 1 consisted of 60 patients who received a combination of 3% hypertonic sterile saline solution and 0.01% hyaluronic acid (Ingasalin® ) (1 ampule of 5 ml solution administered twice a day for 5 days) via nebulizer. Group 2 consisted of 60 patients who received Ambroxol solution for inhalation at a dose appropriate for the patient's age via nebulizer. Objective signs of the disease (cough frequency, productivity (dry/wet) cough, auscultatory lung findings (presence of rales, character of rales)) were assessed dynamically on days 1, 3, 5, and 7 of treatment using a scoring system for symptoms and noting adverse events (if they occurred). Results. By the 3rd day of treatment, the majority of children (85%) in the Ingasalin® group showed a more pronounced regression in both daytime and nighttime cough. In the Ingasalin® group, daytime cough decreased from 3.9±0.5 to 1.8±0.03 points and nighttime cough decreased from 2.8±0.4 to 0.9±0.04 points compared to the comparison group (Ambroxol): reduction of daytime cough from 4.1±0.4 to 2.4±0.02 points and nighttime cough from 2.67±0.2 to 1.6±0.05 points (p<0.05). By the 5th day of treatment, a significant reduction in the severity of daytime and nighttime cough by less than 1 point was noted in children in both groups, with no statistically significant differences between the groups. According to patient diaries, by the 7th day of treatment, cough was absent in 74% of children. Clinical assessment of treatment showed that by the 7th day of observation, recovery was observed in 85% of children in the Ingasalin® group, while in the comparison group, it was observed in 75%. Complete absence of cough was considered the criterion for recovery. Adverse events during treatment in both groups were comparable. Conclusions: The conducted study demonstrated that a 3% hypertonic solution in combination with high molecular weight hyaluronic acid (Ingasalin® 3%) is an effective solution in the treatment of acute bronchitis accompanied by cough in children with respiratory tract infections (RTIs), and even surpasses the synthetic mucoregulatory drug (ambroxol) in terms of effectiveness and onset of action speed.

cough, acute respiratory infection (ARI), acute bronchitis, children, therapy, hypertonic solution

1. Morice A., Kardos P.Comprehensive evidence-based review on European antitussives. BMJ Open Respir Res. 2016 Aug 5;3(1): e000137. doi: 10.1136/bmjresp-2016-000137.

2. Geppe N.A. [A complex of algorithms for drug therapy of respiratory diseases “Cough Trajectory” - 3rd ed.]. Moscow. Tinkomarketing, 2023. 116P. (in Russ.)@@ Комплекс алгоритмов лекарственной терапии заболеваний дыхательных путей «Траектория кашля». Методическое пособие для врачей под ред. Геппе Н. А. - 3-е изд., доп. - Москва: Тинкомаркетинг, 2023. - 116 стр.

3. Begic E., Begic Z., Dobraca A., Hasanbegovic E. Productive Cough in Children and Adolescents - View from Primary Health Care System. Med Arch. 2017 Feb;71(1):66-68. doi: 10.5455/medarh.2017.71.66-68.

4. Chang A.B., Oppenheimer J. J., Weinberger M. M., Rubin B. K., Grant C. C., Weir K., Irwin R. S.; CHEST Expert Cough Panel. Management of Children With Chronic Wet Cough and Protracted Bacterial Bronchitis: CHEST Guideline and Expert Panel Report. Chest. 2017 Apr;151(4):884-890. doi: 10.1016/j.chest.2017.01.025.

5. Smith S.M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database Syst Rev. 2014 Nov 24;2014(11): CD001831. doi: 10.1002/14651858.CD001831.pub5.

6. Shakhnazarova M. D., Geppe N. A., Ozerskaya I. V., Grebeneva I. V., Kolosova N. G., Shatalina S. I., Frolkova E. V., Batyreva O. V., Fidanyan S. E. Mucoactive drugs in the treatment of respiratory diseases in children. Pharmateka. 2023;30(1/2): 32-37. doi: 10.18565/pharmateca.2023.1-2.32-37.@@ Шахназарова М. Д., Геппе Н. А., Озерская И. В., Гребенева И. В., Колосова Н. Г., Шаталина С. И., Фролкова Е. В., Батырева О. В., Фиданян С. Е. Мукоактивные средства в терапии респираторных заболеваний у детей. Фарматека. 2023. Т. 30. № 1/2. С. 32-37.

7. European Medicine Agencies. Revised assessment report: Ambroxol and bromhexine containing medicinal products 2015. Available from: https://www.ema.europa.eu/en/documents/referral/ambroxol-bromhexine-article-31-referral-pracassessment-report_en.pdf

8. Goralski J.L., Wu D., Thelin W. R., Boucher R. C., Button B. The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652. doi: 10.1183/13993003.02652-2017.

9. Máiz Carro L., Martínez-García M. A. Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619866102. doi: 10.1177/1753466619866102.

10. Instructions for use of the medical device. Hypertonic sterile solution for inhalation Ingasalin according. TS No 21.20.23-009-64260974-2018. (in Russ.)@@ Инструкция по применению медицинского изделия. Раствор для ингаляций гипертонический стерильный Ингасалин по Ту 21.20.23-009-64260974-2018.

11. Lamas A., Marshburn J., Stober V. P., Donaldson S. H., Garantziotis S. Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease. Respir Res. 2016 Oct 3;17(1):123. doi: 10.1186/s12931-016-0442-4.

12. Michon A.L., Jumas-Bilak E., Chiron R., Lamy B., Marchandin H. Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients. PLoS One. 2014 Feb 28;9(2): e90164. doi: 10.1371/journal.pone.0090164.

13. Denisova A. R., Kolosova N. G., Grebeneva I. V., Denisova V. D., Glukhova M. V., Lurie E. V. Application of hypertonic saline in children with acute bronchitis. Meditsinskiy sovet = Medical Council. 2021;(17):78-84. (In Russ.) doi: 10.21518/2079-701X-2021-17-78-84.@@ Денисова А. Р., Колосова Н. Г., Гребенева И. В., Денисова В. Д., Глухова М. В., Лурье Е. В. Применение гипертонического раствора у детей с острым бронхитом. Медицинский совет. 2021. № 17. С. 78-84. doi: 10.21518/2079-701X-2021-17-78-84.

14. Zaitsev A. A., Kulikova N. A., Filon E. A., Budoragin I. E., Bednova V. E., Sardalova R. E. Clinical efficacy of mucoactive therapy with 7% hypertonic saline in patients with acute bronchitis. Meditsinskiy sovet = Medical Council. 2022;(23):136-141. (In Russ.) doi: 10.21518/2079-701X-2022-16-23-136-141.@@ Зайцев А. А., Куликова Н. А., Филон Е. А., Будорагин И. Е., Беднова В. Е., Сардалова Р. Э. Клиническая эффективность мукоактивной терапии 7%-м гипертоническим раствором у пациентов с острым бронхитом. Медицинский Совет. 2022;(23):136-141. doi: 10.21518/2079-701X-2022-16-23-136-141.